CERUS CORPORATION (NASDAQ:CERS) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition |
On May3, 2017, Cerus Corporation (the Company) announced its
financial results for its first quarter ended March31, 2017. A
copy of the Companys press release, entitled Cerus Corporation
Reports First Quarter 2017 Results, is furnished to Item 2.02 as
Exhibit 99.1 hereto.
The information in this report, including the exhibit hereto,
shall not be deemed to be filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of Section11 and 12(a)(2) of the Securities
Act of 1933, as amended. The information contained herein and in
the accompanying exhibit shall not be incorporated by reference
into any filing with the U.S. Securities and Exchange Commission
made by the Company, whether made before or after the date
hereof, except as shall be expressly set forth by specific
reference in such filing.
| Item9.01 | Financial Statements and Exhibits |
| (d) | Exhibits. |
The following exhibit is furnished with this report:
| 99.1 |
Press release, dated May3, 2017, entitled Cerus Corporation Reports First Quarter 2017 Results. |
2
About CERUS CORPORATION (NASDAQ:CERS)
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells. CERUS CORPORATION (NASDAQ:CERS) Recent Trading Information
CERUS CORPORATION (NASDAQ:CERS) closed its last trading session down -0.10 at 4.24 with 644,540 shares trading hands.